(Q37516784)

English

Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies

scientific article published on 02 January 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

2 references

23 March 2019

22 June 2019

0 references

Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies (English)

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

0 references

0 references

multiple drug resistance

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

extensively drug-resistant tuberculosis

1 reference

based on heuristic

inferred from title

author name string

Thomas J Hwang

1

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Svetlana Dotsenko

2

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Azizkhon Jafarov

3

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Karin Weyer

4

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Dennis Falzon

5

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Kaspars Lunte

6

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Paul Nunn

7

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Ernesto Jaramillo

8

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Salmaan Keshavjee

9

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Douglas F Wares

10

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

2 January 2014

3 references

Europe PubMed Central

PMC publication ID

20 August 2017

23 March 2019

22 June 2019

2 references

Europe PubMed Central

PMC publication ID

20 August 2017

22 June 2019

4

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

e004143

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

copyright license

Creative Commons Attribution-NonCommercial

2 references

23 March 2019

22 June 2019

on focus list of Wikimedia project

0 references

Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Clofazimine: current status and future prospects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Measuring inconsistency in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Antimycobacterial activities of riminophenazines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Antituberculosis activities of clofazimine and its new analogs B4154 and B4157

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Meta-analysis in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

23 August 2017

Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

6 September 2017

Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

6 September 2017

Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

6 September 2017

Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

6 September 2017

Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

6 September 2017

Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

14 September 2017

Adverse drug reactions: definitions, diagnosis, and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

28 September 2017

Synergistic activities of antituberculous drugs with cerulenin and trans-cinnamic acid against Mycobacterium tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

28 September 2017

"Guide to eliminate leprosy as a public health problem" (first edition, 2000, World Health Organization).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

25 June 2018

Clofazimine therapy for lepromatous leprosy: a historical perspective.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

25 June 2018

High risk of drug-resistant tuberculosis when first-line therapy fails in a high HIV prevalence setting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

2 September 2018

Totally drug-resistant tuberculosis (TDR-TB) in India: every dark cloud has a silver lining

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

2 September 2018

Totally drug-resistant tuberculosis in India.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

2 September 2018

Outcome of treatment of multidrug resistant tuberculosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

2 September 2018

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3902362

3 December 2018

Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands

1 reference

https://pubmed.ncbi.nlm.nih.gov/24384902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A New Series of Phenazines (Rimino-Compounds) With High Antituberculosis Activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/24384902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antituberculosis activity in the phenazine series. II. N3-substituted anilinoaposafranines (rimino-compounds) and some derivatives

1 reference

https://pubmed.ncbi.nlm.nih.gov/24384902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Absorption, distribution and retention of the riminocompounds in the experimental animal

1 reference

https://pubmed.ncbi.nlm.nih.gov/24384902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antituberculous activity of rimino compound of the phenazine series

1 reference

https://pubmed.ncbi.nlm.nih.gov/24384902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Notice of retraction. Role of clofazimine in the treatment of multidrug-resistant tuberculosis: a retrospective observational cohort assessment

1 reference

https://pubmed.ncbi.nlm.nih.gov/24384902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters

1 reference

https://pubmed.ncbi.nlm.nih.gov/24384902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tuberculosis chemotherapy : present situation, possible solutions, and progress towards a TB-free world

1 reference

https://pubmed.ncbi.nlm.nih.gov/24384902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current approaches and future directions in the treatment of leprosy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24384902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Experimental Properties of G 30 320 (B 663) - a New Anti-leprotic Agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/24384902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/BMJOPEN-2013-004143

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37516784&oldid=2168065399"